JP2009530257A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009530257A5 JP2009530257A5 JP2008558913A JP2008558913A JP2009530257A5 JP 2009530257 A5 JP2009530257 A5 JP 2009530257A5 JP 2008558913 A JP2008558913 A JP 2008558913A JP 2008558913 A JP2008558913 A JP 2008558913A JP 2009530257 A5 JP2009530257 A5 JP 2009530257A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- cns
- compound
- sina
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0605337.5A GB0605337D0 (en) | 2006-03-17 | 2006-03-17 | Treatment of CNS conditions |
| GB0605337.5 | 2006-03-17 | ||
| PCT/GB2007/050128 WO2007107789A2 (en) | 2006-03-17 | 2007-03-16 | Treatment of cns conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013161765A Division JP5923466B2 (ja) | 2006-03-17 | 2013-08-02 | Ｃｎｓ状態の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009530257A JP2009530257A (ja) | 2009-08-27 |
| JP2009530257A5 true JP2009530257A5 (https=) | 2010-03-11 |
| JP5781722B2 JP5781722B2 (ja) | 2015-09-24 |
Family
ID=36292900
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008558913A Active JP5781722B2 (ja) | 2006-03-17 | 2007-03-16 | Ｃｎｓ状態の治療 |
| JP2013161765A Active JP5923466B2 (ja) | 2006-03-17 | 2013-08-02 | Ｃｎｓ状態の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013161765A Active JP5923466B2 (ja) | 2006-03-17 | 2013-08-02 | Ｃｎｓ状態の治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8871729B2 (https=) |
| EP (1) | EP2004823B1 (https=) |
| JP (2) | JP5781722B2 (https=) |
| KR (2) | KR101669944B1 (https=) |
| CN (1) | CN101448944B (https=) |
| AU (1) | AU2007228570B2 (https=) |
| CA (1) | CA2645120C (https=) |
| ES (1) | ES2582649T3 (https=) |
| GB (1) | GB0605337D0 (https=) |
| IL (1) | IL194114A (https=) |
| MX (1) | MX2008011731A (https=) |
| RU (1) | RU2426544C2 (https=) |
| WO (1) | WO2007107789A2 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008124066A1 (en) * | 2007-04-05 | 2008-10-16 | The J. David Gladstone Institutes | Agents that reduce neuronal overexcitation |
| WO2010080452A2 (en) | 2008-12-18 | 2010-07-15 | Quark Pharmaceuticals, Inc. | siRNA COMPOUNDS AND METHODS OF USE THEREOF |
| EP3626823A1 (en) * | 2009-09-11 | 2020-03-25 | Ionis Pharmaceuticals, Inc. | Modulation of huntingtin expression |
| DK2504435T3 (da) | 2009-11-26 | 2019-12-09 | Quark Pharmaceuticals Inc | Sirna-forbindelser omfattende terminale substitutioner |
| US20110135613A1 (en) | 2009-12-03 | 2011-06-09 | The J. David Gladstone Institutes | Methods for treating apolipoprotein e4-associated disorders |
| EP2510098B1 (en) | 2009-12-09 | 2015-02-11 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the cns |
| AU2011219029B2 (en) * | 2010-02-26 | 2017-02-02 | Columbia University | Methods and compositions for the detection and treatment of cancer involving miRNAs and miRNA inhibitors and targets |
| RU2664452C2 (ru) | 2010-04-19 | 2018-08-17 | Нлифе Терапеутикс, С.Л. | Конъюгат, медицинское средство и способы лечения и/или профилактики депрессии и болезни, связанной с отложением телец Леви |
| EP2380595A1 (en) | 2010-04-19 | 2011-10-26 | Nlife Therapeutics S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| AU2011338682B2 (en) | 2010-12-06 | 2017-04-27 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising threose modifications |
| WO2012123819A1 (en) * | 2011-03-15 | 2012-09-20 | Optinose As Et Al | Nasal delivery |
| CA2851761C (en) * | 2011-10-14 | 2021-06-15 | Centre National De La Recherche Scientifique | Method of diagnosis, prognostic or treatment of neurodegenerative diseases |
| EP2822600A4 (en) * | 2012-03-09 | 2016-04-06 | Univ Northeastern | METHOD OF DISTRIBUTING NUCLEIC ACID ANOPARTICLES TO THE CENTRAL NERVOUS SYSTEM FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
| AU2013203395A1 (en) * | 2012-03-30 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome |
| US9611473B2 (en) | 2012-09-12 | 2017-04-04 | Quark Pharmaceuticals, Inc. | Double-stranded nucleic acid compounds |
| AU2013336581A1 (en) | 2012-10-26 | 2015-06-11 | Nlife Therapeutics, S.L. | Compositions and methods for the treatment of Parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types |
| ES2807379T3 (es) * | 2013-03-14 | 2021-02-22 | Ionis Pharmaceuticals Inc | Composiciones y métodos para regular la expresión de Tau |
| JP2016523980A (ja) * | 2013-07-11 | 2016-08-12 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | タウ発現を抑制するマイクロｒｎａ |
| TWI772856B (zh) | 2013-07-19 | 2022-08-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| EP3027223A1 (en) | 2013-07-31 | 2016-06-08 | QBI Enterprises Ltd. | Methods of use of sphingolipid polyalkylamine oligonucleotide compounds |
| JP2017505756A (ja) * | 2013-12-13 | 2017-02-23 | ザ ジェネラル ホスピタル コーポレイション | 可溶性高分子量（ｈｍｗ）タウ種およびその用途 |
| EP3274456B1 (en) * | 2015-03-25 | 2020-06-24 | Università Degli Studi Di Trento | Rna interference mediated therapy for neurodegenerative diseases |
| PH12018501207B1 (en) | 2015-12-21 | 2024-02-23 | Novartis Ag | Compositions and methods for decreasing tau expression |
| ES2963428T3 (es) | 2016-09-29 | 2024-03-27 | Biogen Ma Inc | Compuestos y métodos para reducir la expresión de Tau |
| BR112020006671A2 (pt) * | 2017-10-03 | 2020-12-01 | Prevail Therapeutics, Inc. | terapias genéticas para distúrbios lisossômicos |
| KR102709597B1 (ko) | 2017-10-03 | 2024-09-26 | 프리베일 테라퓨틱스, 인크. | 리소좀 장애를 위한 유전자 요법 |
| KR20200131263A (ko) | 2018-03-13 | 2020-11-23 | 얀센 파마슈티카 엔.브이. | 변형 올리고뉴클레오티드 및 타우병증에서의 사용 방법 |
| AU2021238319A1 (en) * | 2020-03-18 | 2022-10-06 | University Of Massachusetts | Oligonucleotides for MAPT modulation |
| AU2021246024A1 (en) * | 2020-03-30 | 2022-10-27 | Alnylam Pharmaceuticals, Inc. | Microtubule associated protein Tau (MAPT) iRNA agent compositions and methods of use thereof |
| CN113817728A (zh) * | 2020-06-19 | 2021-12-21 | 四川大学华西医院 | 一种有效干扰Tau蛋白表达的重组慢病毒及其应用 |
| KR20240067943A (ko) * | 2021-09-24 | 2024-05-17 | 알닐람 파마슈티칼스 인코포레이티드 | 미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법 |
| CN119173631A (zh) * | 2022-05-12 | 2024-12-20 | 迪克纳制药公司 | 用于抑制mapt表达的组合物和方法 |
| KR20250129743A (ko) * | 2022-12-29 | 2025-08-29 | 보이저 테라퓨틱스, 인크. | Mapt를 조절하기 위한 조성물 및 방법 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2116460A1 (en) | 1993-03-02 | 1994-09-03 | Mitsubishi Chemical Corporation | Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being |
| US6410046B1 (en) * | 1996-11-19 | 2002-06-25 | Intrabrain International Nv | Administering pharmaceuticals to the mammalian central nervous system |
| WO2002086105A1 (en) | 2001-04-20 | 2002-10-31 | Chiron Corporation | Delivery of polynucleotide agents to the central nervous sysstem |
| US20050159376A1 (en) | 2002-02-20 | 2005-07-21 | Slrna Therapeutics, Inc. | RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA) |
| IL143379A (en) | 2001-05-24 | 2013-11-28 | Yissum Res Dev Co | Oligonucleotide against human ache isoform r and its uses |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| GB2406568B (en) | 2002-02-20 | 2005-09-28 | Sirna Therapeutics Inc | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| CA2482904A1 (en) | 2002-04-18 | 2003-10-23 | Lynkeus Biotech Gmbh | Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
| US20040254146A1 (en) | 2002-05-21 | 2004-12-16 | Nastech Pharmaceutical Company Inc. | Carboxylate salts of galantamine and their pharmaceutical use |
| US20030225031A1 (en) | 2002-05-21 | 2003-12-04 | Quay Steven C. | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| US20050042646A1 (en) | 2002-08-05 | 2005-02-24 | Davidson Beverly L. | RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
| US20050106731A1 (en) * | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
| US20040241854A1 (en) | 2002-08-05 | 2004-12-02 | Davidson Beverly L. | siRNA-mediated gene silencing |
| CA2500224C (en) | 2002-09-25 | 2015-04-28 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
| MXPA05003287A (es) | 2002-09-28 | 2005-07-05 | Massachusetts Inst Technology | Influenza terapeutica. |
| ES2334125T3 (es) * | 2002-11-04 | 2010-03-05 | University Of Massachusetts | Interferencia de arn especifico de alelos. |
| US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
| EP2508608A1 (en) * | 2003-06-09 | 2012-10-10 | Alnylam Pharmaceuticals Inc. | Method of treating neurodegenerative disease |
| US20060241072A1 (en) | 2003-06-20 | 2006-10-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds for use in gene modulation |
| CA2528963A1 (en) | 2003-06-27 | 2005-01-13 | Sirna Therapeutics, Inc. | Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina) |
| WO2005014815A1 (en) * | 2003-08-08 | 2005-02-17 | President And Fellows Of Harvard College | siRNA BASED METHODS FOR TREATING ALZHEIMER’S DISEASE |
| WO2005045037A2 (en) | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2005105995A2 (en) | 2004-04-14 | 2005-11-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20050265927A1 (en) | 2004-05-17 | 2005-12-01 | Yale University | Intranasal delivery of nucleic acid molecules |
| WO2006041922A2 (en) | 2004-10-08 | 2006-04-20 | Dara Biosciences, Inc. | Agents and methods for administration to the central nervous system |
-
2006
- 2006-03-17 GB GBGB0605337.5A patent/GB0605337D0/en not_active Ceased
-
2007
- 2007-03-16 JP JP2008558913A patent/JP5781722B2/ja active Active
- 2007-03-16 EP EP07733553.7A patent/EP2004823B1/en active Active
- 2007-03-16 AU AU2007228570A patent/AU2007228570B2/en active Active
- 2007-03-16 US US12/293,230 patent/US8871729B2/en active Active
- 2007-03-16 WO PCT/GB2007/050128 patent/WO2007107789A2/en not_active Ceased
- 2007-03-16 CN CN200780017978.7A patent/CN101448944B/zh active Active
- 2007-03-16 KR KR1020087025174A patent/KR101669944B1/ko active Active
- 2007-03-16 KR KR1020147013792A patent/KR101605144B1/ko active Active
- 2007-03-16 RU RU2008141162/15A patent/RU2426544C2/ru active
- 2007-03-16 CA CA2645120A patent/CA2645120C/en active Active
- 2007-03-16 MX MX2008011731A patent/MX2008011731A/es active IP Right Grant
- 2007-03-16 ES ES07733553.7T patent/ES2582649T3/es active Active
-
2008
- 2008-09-15 IL IL194114A patent/IL194114A/en active IP Right Grant
-
2013
- 2013-08-02 JP JP2013161765A patent/JP5923466B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009530257A5 (https=) | ||
| RU2008141162A (ru) | Лечение нарушений цнс | |
| Wei et al. | Non-coding RNAs as regulators in epigenetics | |
| Fuchs et al. | 4sUDRB-seq: measuring genomewide transcriptional elongation rates and initiation frequencies within cells | |
| Miniarikova et al. | Design, characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for Huntington's disease | |
| Xu et al. | Downregulations of B‐cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG‐05MG | |
| Ambesajir et al. | RNA interference: A futuristic tool and its therapeutic applications | |
| JP6295232B2 (ja) | 修飾を有するｄｓＲＮＡによる遺伝子発現の特異的な阻害のための組成物および方法 | |
| JP2009509548A5 (https=) | ||
| JP2022078069A (ja) | 二本鎖ＲＮＡによるα－１アンチトリプシンの特異的阻害のための方法及び組成物 | |
| Boudreau et al. | Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease | |
| McDermott et al. | The therapeutic potential of microRNAs: disease modulators and drug targets | |
| JP2009532392A5 (https=) | ||
| JP7102557B2 (ja) | Ｔａｕ発現調節用オリゴヌクレオチド | |
| JP2014511686A5 (https=) | ||
| JP2018507866A (ja) | マイクロｒｎａを有効成分として含む癌治療用医薬組成物 | |
| JP2010512747A5 (https=) | ||
| CN108366966A (zh) | 用于调节基因表达的多核苷酸纳米颗粒及其用途 | |
| Morales et al. | Contribution of host miRNA-223-3p to SARS-CoV-induced lung inflammatory pathology | |
| Mirihana Arachchilage et al. | Targeting of G-quadruplex harboring pre-miRNA 92b by LNA rescues PTEN expression in NSCL cancer cells | |
| JP2016520310A5 (https=) | ||
| US10934547B2 (en) | Use of trinucleotide repeat RNAs to treat cancer | |
| Lee et al. | Effects of polymorphisms in the porcine micro RNA MIR206/MIR133B cluster on muscle fiber and meat quality traits | |
| Lisowiec-Wąchnicka et al. | A systematic study on the influence of thermodynamic asymmetry of 5′-ends of siRNA duplexes in relation to their silencing potency | |
| WO2011142798A3 (en) | Methods of preparing targeted aptamer prodrugs |